Klaribros

Clarithromycin, the active ingredient in Klaribros, is a macrolide antibiotic presented as a tablet for oral use. It treats a range of bacterial infections, including community‑acquired pneumonia, acute bacterial sinusitis, acute otitis media, skin and soft‑tissue infections, and is part of combination therapy for Helicobacter pylori eradication.

GNH USA supplies Klaribros as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Clarithromycin is used to treat bacterial infections affecting the respiratory tract, ears, skin and gastrointestinal system.

- Community‑acquired pneumonia: eradicates the causative bacteria, improving respiratory function and reducing disease duration. - Acute bacterial sinusitis: relieves sinus inflammation by eliminating the infecting organisms. - Acute otitis media: clears middle‑ear infection, alleviating pain and hearing loss. - Skin and soft‑tissue infections: combats Gram‑positive and some Gram‑negative bacteria, promoting wound healing. - Helicobacter pylori eradication (in combination therapy): contributes to bacterial clearance, supporting ulcer healing.

Clarithromycin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild stomach upset often occurring after the first dose. - Diarrhea: loose stools that may be self‑limiting. - Abdominal pain: cramping or discomfort in the stomach area. - Taste disturbance: altered or metallic taste.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - QT interval prolongation: may lead to cardiac arrhythmias. - Clostridioides difficile infection: severe colitis following disruption of gut flora.

When prescribing Klaribros, clinicians should consider several safety factors.

- Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic disease: use with caution; monitor liver enzymes. - Pregnancy: classified as Category B, generally considered safe but use only if clearly needed. - Concomitant QT‑prolonging drugs: avoid co‑administration to reduce arrhythmia risk. - Allergic history: discontinue if signs of hypersensitivity appear. - Store at room temperature: keep in original container, protect from moisture and light.

Clarithromycin interacts with several medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Erythromycin: additive macrolide effect increases risk of QT prolongation. - Cisapride: combined use can cause serious cardiac arrhythmias. - Theophylline: clarithromycin inhibits metabolism, raising theophylline concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Statins (simvastatin, lovastatin): increased risk of myopathy; consider dose adjustment.